# A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients

> **NCT01305239** · — · TERMINATED · sponsor: **Pfizer** · enrollment: 398 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Aromasin

## Key facts

- **NCT ID:** NCT01305239
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 398 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2012-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01305239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01305239, "A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01305239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*